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Abstract
Background: To assess progress in improving affordability of medicines since the introduction of
mandatory health insurance in the Republic of Moldova.
Method: Using data from national health insurance, we estimate affordability of partially reim-
bursed medicines for the treatment of non-communicable diseases, and analyse which factors con-
tributed to changes in affordability.
Results: Affordability of subsidized medicines improved over time. In 2013, it took a median of 0.84
days of income for the lowest income quintile (ranging from 0 to 3.32 days) to purchase 1 month of
treatment for cardiovascular conditions in comparison to 1.85 days in 2006. This improvement
however was mainly driven by higher incomes rather than deeper coverage through the reim-
bursement list.
Conclusion: If mandatory health insurance is to improve affordability of medicines for the
Moldovan population, more funds need to be (re-)allocated to enable higher percentage coverage
of essential medicines and efficiencies need to be generated within the health system. These
should include a budget reallocation between secondary and primary care, strengthening primary
care to manage chronic conditions and raise population awareness, implementation of evidence-
based selection and quality use of medicines in both outpatient and inpatient settings, improving
monitoring and regulation of prices and the supply chain; and alignment of national treatment
guidelines and clinical practice with international best practices and evidence-based medicine.
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Introduction
Medicines tend to represent the largest component of out-of-pocket
payments expenditure on health, particularly in countries with in-
complete health insurance (Ibrahimov et al. 2010; Khodjamurodov
and Rechel 2010; Turcanu et al. 2012; Richardson et al. 2013).
Assessing their affordability for the population is therefore very im-
portant and one of the complementary national indicators of the sus-
tainable development goal agenda (3.31) (Sustainable Development
Knowledge Platform 2015).
Affordability of medicines has been studied using both qualita-
tive and quantitative methods and different indicators. Qualitative
methods usually explore interviewees’ perceptions of affordability
(Shafiq et al. 2011; Searles et al. 2013; Naci et al. 2014; Vialle-
Valentin et al. 2015), whereas quantitative methods tend to bench-
mark the cost of a medicine against some threshold. The WHO/HAI
method evaluates affordability of essential medicines by estimating
the number of days of wage needed for the lowest paid public sector
worker to purchase 1 month of treatment for a chronic condition or
a course of treatment for an acute condition (WHO and HAI 2008).
Medicines costing more than 1 day of work are considered unafford-
able. The catastrophic expenditure and the impoverishment method
both focus on the percentage of the population which would experi-
ence catastrophic health expenditure or impoverishment if they had
to purchase the pharmaceutical treatment under analysis. Studies on
affordability of medicines have defined expenditure (on medicines)
as catastrophic if it exceeded 5% of daily income and a household
to become impoverished if the residual income after purchasing
medicines was less than US$1.25 or US$2 per day (Nie¨ns et al.
2010, 2012). These two methods have been initially proposed to
study affordability of health care as a whole (Wagstaff and van
Doorslaer 2003) and applied in a number of studies on the subject
using different thresholds (Xu et al. 2003; Su et al. 2006;
Limwattananon et al. 2007; Somkotra and Lagrada 2008; Sun et al.
2009; van Doorslaer et al. 2006). Other studies compared unit costs
of cancer medicines with months of income (Roy et al. 2012) and
cost of treatment with monthly per capita expenditure (Yohana
et al. 2011) .
In low- and middle-income countries, evidence on affordability
of medicines is limited. Most available studies have either been
cross-sectional or baseline and follow-up and they have often not
considered that some medicines may be at least partially reimbursed.
In Republic of Moldova, the only study on affordability of medi-
cines was the 2011 WHO/HAI survey (WHO 2012). The country
has introduced the first list of compensated medicines in 2005 as
part of mandatory health insurance. However, despite spending on
medicines is the largest component of private expenditure on health,
very little analysis of what the introduction of mandatory health in-
surance has delivered in terms of increased affordability of NCD
medicines for patients has been conducted. In an attempt to address
this gap, we analysed changes in affordability of medicines following
the introduction of mandatory health insurance in the Republic of
Moldova.
We use a modified version of the WHO/HAI methodology which
takes into account that part of the medicines cost is covered by man-
datory health insurance. This study does not claim to provide a su-
perior method to the existing methods described, but rather to
contribute to the research area of medicines affordability with longi-
tudinal data in a country which, like many others, is working to-
wards achieving universal health coverage. As other authors have
noted, due to the ambiguous nature of affordability, it is best to be
analysed from different perspective and using different metrics
(Cameron et al. 2009a). The catastrophic expenditure and impover-
ishment methods take into account that households need to cover
basic needs like food which will decrease the amount of income
available for medicines. Further, they take into account the income
distribution of the population. The WHO/HAI method only con-
siders the wage of the lowest paid public sector worker, which was
acknowledged to be higher that what some groups of the population
earn (Cameron et al. 2009b; Nie¨ns and Brouwer 2009). In addition,
it does not consider other basic expenses households experience. Its
main strengths are the straightforward interpretation and a numer-
ical value (days of wage) replacing the cost of medicine but allowing
for comparison across medicines. For these last two reasons, and be-
cause we want to compare how much more affordable medicines
have become over time, and not only the percentage of the popula-
tion experiencing either catastrophic expenditure or impoverish-
ment, we decided to use a modified version of the WHO/HAI
metric. In our analysis, we use health insurance data which enable
us to take reimbursement into account and estimate affordability for
different income and expenditure quintiles.
National health policy context relevant to
medicines
Mandatory health insurance was introduced in 2004 in the Republic
of Moldova. A year later the first reimbursement list for outpatient
medicines was introduced. Inpatient medicines are in principle cov-
ered at 100% for all insured patients. However, evidence from a na-
tional survey in 2011 showed that 16.9% of the respondents had to
purchase their medicines while in hospitals and 29.6% received only
some of the required medicines free of charge and had to purchase
the remaining ones (PAS Centre 2011).
According to the estimates of the National Health Insurance
Company, in 2013, 83.2% of the population was covered (CNAM
2012). However, these estimates should be taken with caution be-
cause of difficulties in estimating the denominator due to migration.
Using a different methodology and including only people aged 18–
69 years (i.e. excluding the children and the elderly who are insured
by the Government), the 2013 WHO STEPS survey estimated that
Key Messages
• Affordability of partially compensated medicines for the treatment of NCDs has improved since the introduction of the
first reimbursement list in 2006 for all income and expenditure quintiles.
• This improvement, however, was mainly driven by higher incomes and expenditure rather than deeper coverage
through the reimbursement list.
• Simply increasing funding for medicines is likely not to deliver the expected results, nor to be a feasible or sustainable
solution, if broader issues affecting use of medicines are not addressed.
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only 66.4% (95% CI: 64.1–68.8) of all respondents aged 18–69
years were insured.
Improving access to medicines and financial protection are high
on the Moldovan Government’s agenda. Moldova has a health care
system development strategy for 2008–17 which contains a specific
objective related to access to medicines, namely to increase budget
allocation for compensated medicines and to improve resource allo-
cation mechanisms (Government of the Republic of Moldova 2007).
This will be monitored by the actual increase in budget though no
concrete target was set. The National Health Insurance Company
has also been putting emphasis on improving resource allocation for
medicines in its institutional development strategies and has also set
specific targets including the gradual increase in budget allocation
for medicines to 10% by 2017 and a reduction in the proportion of
private spending on medicines from 71.5% in 2014 to 65% by 2017
(CNAM 2012, 2013, 2014).
In this study, we aim to answer the following research question:
How has financial protection against out-of-pocket payments in the
Republic of Moldova changed following the introduction of manda-
tory health insurance? As medicines tend to represent a major share
of out-of-pocket payments on health, this question is relevant to a
number of countries currently trying to increase financial protection
through the introduction of mandatory health insurance.
Methods
Medicines sample selection and data sources
The affordability analysis focused on cardiovascular and respiratory
medicines (the latter only for adults as children are covered at
100%) dispensed in outpatient settings because these medicines are
included in the reimbursement list but subject to co-payments.
Cancer medicines, which are dispensed at the hospital, and diabetes
medicines are reimbursed at 100% (initially diabetes medicines were
reimbursed at 90%) and were therefore not included in the afford-
ability analysis. Claims data on compensated medicines between
2006 and 2013 were obtained upon request from National Health
Insurance Company. This included information on the number of
units (tablets, inhalers, etc.), total expenditure and total reimburse-
ment for different medicines–formulations included in the reim-
bursement list.
Estimation of affordability
We applied a modified version of the WHO/HAI methodology to
measure affordability. Instead of estimating only how affordable
medicines are for the lowest paid public sector worker, we estimated
affordability for different income quintiles. To do this we used an-
nual data on total spending and total reimbursement for NCD medi-
cines included in the outpatient reimbursement list, but subject to
co-payments. With this information, we calculated how many days
of monthly disposable income (cash and in-kind) and expenditure,
as estimated by household budget survey (NBS 2015), were neces-
sary to purchase 1 month of treatment for different income
quintiles.
More specifically, we used data on the number of units (tablets,
inhalers, etc.) to estimate the total milligrams (mg) of active ingredi-
ent reimbursed per International Non-Proprietary Name (INN).
This total was then divided by the WHO defined daily dose (DDD)
for that INN (WHO Collaborating Centre for Drug Statistics
Methodology 2013) to estimate the number of DDDs that were at
least partially reimbursed and the average amount paid out-of-
pocket per month. We then divided the amount paid out-of-pocket
by the daily disposable income of different income quintiles. To test
the sensitivity of the results to possible underreporting of income
due to remissions, informal economy, etc., we estimated affordabil-
ity also by expenditure quintiles using household budget survey
data.
Steps
1. Patient cost per month: Patient cost per DDD*30.4 days
Patient cost per DDD ¼ Total patient co-payment for a particu-
lar medicine/Number of DDDs dispensed of this medicines
Number of DDD dispensed for a particular medicine ¼
Medicine strength (mg)*Number of units dispensed/WHO DDD
for this medicine
30.4 ¼ average number of days in a month (365 days in a year/
12 month).
2. Days of wage needed to purchase 1 month of treatment ¼
Patient cost per month/Daily income or expenditure for different
quintiles.
Results
Affordability of medicines for the treatment of NCDs
included in the reimbursement list
Median affordability for cardiovascular and respiratory medicines
included in the reimbursement list but subject to co-payments im-
proved between 2006 and 2013. In 2006, it took a median of 1.85
days of income for the lowest income quintile to purchase 1 month
of treatment for cardiovascular conditions (Figure 1). For respira-
tory medicines, only aminophylline and salbutamol were reimbursed
100% for children 0–5 and salbutamol 50% for adults. However,
according to expenditure and reimbursement data, 100% of salbuta-
mol was reimbursed suggesting no partially compensated salbuta-
mol was prescribed to adults.
In 2013, it took in median 0.84 days of income to purchase on
month of treatment for cardiovascular and 1.13 days of income for
respiratory conditions. Between 2008 and 2010 affordability of car-
diovascular medicines decreased from 1.32 to 1.45 days of income
and from 1.21 to 2.47 days for respiratory medicines.
Due to remittances from family members living abroad and a
large informal economy, it is likely that the actual individual income
is higher than the one reported in the household budget survey. To
account for this, we estimated affordability using expenditure quin-
tiles rather than income quintiles. Expenditure was lower than in-
come for quintiles 1–2 but higher for quintiles 3–5 in both 2006 and
2013 hinting to under-reporting of income by relatively wealthier in-
dividuals. Although medicines become slightly more affordable for
higher expenditure quintiles, the overall results do not change sub-
stantially (Supplementary Figure S1).
Drivers of medicines affordability
Medicines affordability (as defined in this study) depends on the in-
come or expenditure distribution of the households, prices, of medi-
cines, the percentage reimbursed and the maximum absolute level of
reimbursement by the National Health Insurance Company for dif-
ferent medicines. In the following figures, we show changes in these
variables over time.
All quintiles experienced an increase in their level of income and
expenditure (taking into account inflation). The daily disposable in-
come for households has increased from Lei 13 in 2006 to Lei 30 in
2013 for the lowest income quintile and from Lei 49 in 2006 to Lei
96 for the highest income quintile (Figure 2). This corresponds to
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about a 140% increase for the least wealthy and a 100% increase
for the wealthiest (at 2006 constant values). These findings reflect
very closely the ones for expenditure quintiles, with the main
difference that expenditure for the wealthiest increased only by 70%
(Supplementary Figure S2).
The median price (inflation adjusted) per DDD included in the
reimbursement list remained quite stable between 2006 (MDL1 2.2
per DDD) and 2013 (1.97 Moldovan Lei per DDD) (Figure 3), des-
pite some adjustments in the benefit package which have influenced
the medicines basket composition (supplementary Table 1). There
was a small increase in the median price per DDD of partially com-
pensated respiratory medicines for adults in 2010, from MDL 2.38
to MDL 3.01, which was due at least in part to the introduction of
aminophylline in the reimbursement list for adults (previously only
children were covered at 100%). A more substantial increase in
median price from MDL 2.73 to MDL 4.80 occurred in 2013
following the listing of two more respiratory medicines for adults
(beclometasone and fluticasone).
Despite an increase in the expected level of reimbursement for
selected cardiovascular medicines in 2012, the median expected per-
centage covered remained stable at 50% between 2006 to 2013
(Figure 4). The number of cardiovascular medicines (different INNs)
included in the reimbursement list remained stable at 21 until 2012,
after which it dropped to 18. There was an increase in the expected
level of median reimbursement for respiratory medicines from 50%
to 60% in 2011 and to 70% in 2013. This was accompanied by an
increase in the number of medicines reimbursed from 1 to 2 between
2009 and 2010 and from 2 to 4 between 2012 and 2013.
Respiratory medicines in children were covered at 100% throughout
2006–13 and their number increased from 2 to 4 between 2012 and
2013. Diabetes medicines were initially reimbursed at 90% when
they were first introduced in the reimbursement list in 2010 but
Figure 1. By income quintile: Affordability cardiovascular and respiratory medicines included in the reimbursement list but subject to co-payments.
Notes: Diamonds represent the median value and the vertical bar shows the maximum and minimum values estimated. 1-5 represent wealth quintiles where 1
are the least wealthy and 5 the wealthiest. For comparison purposes, the minimum daily wage used in the WHO/HAI survey (World Health Organization, 2012)
was 20 Moldovan Lei, which happens to correspond quite closely to one day of disposable income of the lowest income quintile (18 MDL in 2012).
Figure 2 Income by quintiles, 2006–2013.
Figure 3 Median price per DDD of medicines included in the reimbursement
list.
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were fully reimbursed from the following year onwards. The list of
diabetes medicines initially included glibenclamide, glimepiride and
metformin, from 2013 insulin was moved into the reimbursement
list (already available free of charge before but vertically procured
through a national programme with separate funding).
Only a certain absolute maximum amount is compensated per
tablet. This means that the actual percentage covered may be higher
or lower than the median expected 50% for cardiovascular medi-
cines. Between 2006 and 2011 there was no noticeable change in the
median maximum compensated sum which remained stable at MDL
0.79 for respiratory medicines and MDL 0.83–0.87 for cardiovascu-
lar medicines (Figure 5). This sum increased in 2012 for
cardiovascular medicines to MDL 1.1 due to higher compensation
temporarily granted to some medicines in this therapeutic group,
but went down again to 0.89 in the following year when coverage
was reduced to 50%. A smaller increase to MDL 0.88 also took
place in 2012 for respiratory medicines due to higher reimbursement
from 50% to 70% for salbutamol.
The actual proportion of total cost reimbursed is determined by
median expected percentage reimbursement set in the list and
the maximum sum compensated. For cardiovascular medicines,
it increased only modestly from 47% in 2006 to 52% in 2012
(Figure 6). The increase was greater for respiratory medicines in
adults, where actual coverage increased from 58% in 2007 to 73%
in 2013.
Discussion
Our analysis of changes in affordability of partially compensated
NCD medicines since the introduction of mandatory health insurance
in the Republic of Moldova showed that increased affordability was
driven by raising household income rather than deeper coverage
through the reimbursement list. The results of the affordability ana-
lysis using national health insurance data show similar results for
2011 to the WHO/HAI survey (for medicines included in both studies)
based on pharmacy retail prices in the same year (WHO 2012). The
latter has to be interpreted with caution though because it did not take
into account that some medicines are at least partially reimbursed by
the National Health Insurance Company for insured patients.
There are several reasons why the reimbursement list has not
achieved deeper coverage for cardiovascular and respiratory (for
adults) medicines over time. For cardiovascular medicines, the
expected percentage coverage for reimbursed medicines has largely
remained unchanged at median 50% between 2006 and 2013
Figure 4Median percentage expected reimbursement by therapeutic group according to the reimbursement list, 2006–13.
Note: This is the expected percentage reimbursement based on the maximum reimbursement sum. The actual percentage reimbursed depends on retail prices
and may be higher or lower than the median expected percentage reimbursement
Figure 5 Median maximum reimbursed sum per DDD by therapeutic group,
2006–13.
Figure 6 Actual proportion of total cost reimbursed.
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(coverage was only briefly increased to 70% and 90% for selected
cardiovascular medicines in 2012) and the same applies for the max-
imum reimbursement sum per tablet. This meant that between 2006
and 2013, actual coverage for partially compensated cardiovascular
medicines, only increased from 47% to 52%. The situation is better
for respiratory medicines in adults. For these, median expected
coverage in the list has increased from 50% to 60% in 2011 and
from 60% to 70% in 2013. However, the median maximum reim-
bursement sum per table has remained stable at 0.79 from 2007 to
2011 and only increased to 0.88 in 2012. Despite this limitation,
there was an increase in the actual proportion covered from 58% in
2007 to 73% in 2013.
The very limited increase in coverage for these medicines is
multifaceted. One issue is funding constraints. In 2013, only 3.9%
of the National Health Insurance Company’s budget was spent on
medicines corresponding to MDL 55 (US$4.4) per insuree. For com-
parison purposes, Estonia, Romania and Scotland spent US$108,
US$68 and US$317 per capita, respectively, on outpatient medicines
in the same year (2014 in Romania). This corresponded to 15%,
22.6% and 11% of the total national health insurance expenditure
in Estonia, Romania and Scotland, respectively [authors’ estimation
based on IDS Scotland (2015), Estonian Health Insurance Fund
(2015) and Alianta pentru sa˘na˘tate din Romaˆnia (2014)]. However,
simply increasing funding for medicines is likely not to deliver the
expected results, nor to be a feasible or sustainable solution, if
broader issues affecting the country’s health system and quality use
of medicines are not addressed. First of all, resources need to be gen-
erated by reducing inefficiencies at secondary care level so that more
funds can be allocated to primary care, including medicines. Once
more funds are available, these need to be spent effectively.
Medicines to be reimbursed need to be selected based cost-effective-
ness criteria, prescribing needs to follow quality use of medicines
principles and better value for money needs to be obtained through
improved pricing as well as supply chain regulation as well as moni-
toring (Sautenkova et al. 2012). The case of salbutamol syrup illus-
trates some of these issues and their inter-linkages (Box 1).
Concrete steps have already been taken to address some of these
issues but many more will be necessary to achieve long-lasting
changes. Guidelines for selecting medicines for reimbursement accord-
ing to evidence-based medicine and cost-effectiveness criteria have
been developed in collaboration with the WHO and approved by the
Ministry of Health in August 2015. A technical Secretariat has been
established within the National Health Insurance Company who will
be responsible to conduct budget impact analyses and assess manufac-
turer submissions to the outpatient reimbursement list.
After conducting country’s first STEPS survey in 2013, which
showed that less than half of the Moldovan population with hyper-
tension is on regular treatment (WHO Regional Office for Europe
2014), and in line with the targets of the Global NCD monitoring
framework (World Health Organization 2015a), the Government of
the Republic of Moldova has agreed with the World Bank to moni-
tor its spending performance against, among other indicators, the
percentage of patients with hypertension who are controlled. With
this target in mind, the Government has increased compensation for
medicines for the treatment of hypertension from 50% to 70%.
Finally, while concrete actions are yet to follow, the need to
reduce inefficiencies in the hospital sector has been highlighted
National Health Care System Development Strategy for 2008–17
(Government of the Republic of Moldova 2007). Further, there
was agreement during a high level meeting of Government offi-
cials and head of health institutions in August 2015 that the re-
sources freed by addressing inefficiencies at hospital level could
be used to strengthen primary care and access to medicines.
Despite its limitations, it is important to recognize that the out-
patient reimbursement list covers, either fully or partially, a number
of essential medicines. Cardiovascular and respiratory medicines
included in the list but subject to co-payments have become more af-
fordable over time and diabetes medicines are fully covered.
Evidence from a study comparing the proportion of the population
foregoing medicines in 2001 and 2010 in selected Former Soviet
Union countries seems to support the positive impact the reimburse-
ment list has had on access over time. The study found the greatest
decline in forgoing medicines in the Republic of Moldova [rate ratio
(RR)¼0.67 (0.63; 0.71)] and Kyrgyzstan [RR¼0.63 (0.60; 0.67)]
(Footman et al. 2014). It also highlighted that improvements were
greatest in countries with more progressive pharmaceutical policies,
despite lower incomes (Footman et al. 2014).
Finally, compared with other Former Soviet Union countries
with similar income levels, the Republic of Moldova spends a much
higher share of gross domestic product on health, 11.7% in 2012
which was the highest among Former Soviet Union countries (World
Health Organization 2014).
Limitations
The income and expenditure data used in this study were taken from
national household budget surveys. These surveys have well-known
limitations. Although the samples of the household budget survey
Box 1. The case of salbutamol syrup for children
Since 2008 salbutamol syrup (2mg/5ml in 150ml) has
been included in the list of reimbursed trade names and
formulations of salbutamol. In 2013, the price per DDD
of this formulation was MDL 8.4, the highest among the
four formulations reimbursed for children. The lowest
cost formulation (100mcg per 200 doses) cost only MDL
0.9 per DDD and, contrary to syrup, is included in the
WHO model list of essential medicines for children
(World Health Organization 2015b). The price of salbuta-
mol syrup in the Republic of Moldova seems to be even
higher than in the United Kingdom (the same trade
name from a UK manufacturer was compared which, in
2013, was the only trade name of salbutamol syrup
reimbursed in the Republic of Moldova). In fact, the ex-
factory price registered as of September 2015 in
Moldova was MDL 30.24 per unit while the NHS net
price per unit in the British National Formulary was GBP
0.73 which corresponds to approximately MDL 22. But
the high price is not the only issue. According to a 2011
review of the literature, oral salbutamol is ineffective in
the treatment of paediatric asthma and is associated
with an increased incidence of adverse events compared
with inhaled formulations. Paediatric masks and spacers
can facilitate administration of inhaled salbutamol to all
patients; therefore, there is no role for oral salbutamol
(Herd 2011). Instead, clinical protocols for family phys-
icians in the Republic of Moldova, recommend oral sal-
butamol (by trade name, not generic name) as first line
emergency treatment in children (Ministerul Sanatatii al
Republicii Moldova 2010). In 2013, syrup accounted for
32% of all DDDs reimbursed for salbutamol in children.
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used in this study were random, they may not necessarily be repre-
sentative of the Moldovan population. Data are based on self-
reporting and no verification takes place. This could for example
affect both reported income and expenditure downwards.
Further, although various definitions of affordability and meth-
ods to estimate it are available, we only used one method. In future
studies, it would be interesting to apply different methods and com-
pare their results.
Conclusion
Affordability of partially compensated medicines for the treatment
of NCDs has improved since the introduction of the first reimburse-
ment list in 2006 for all income and expenditure quintiles. This im-
provement, however, was mainly driven by higher incomes and
expenditure rather than deeper coverage through the reimbursement
list. If the list is to improve affordability of medicines for the
Moldovan population, more funds need to be (re-)allocated to en-
able higher percentage coverage of essential medicines.
Following approval by the Parliament to increase funds for medi-
cines, in November 2015, compensation of hypertensive medicines
was increased from 50% to 70%. This is a welcome step in the right
direction, however, for it to be sustainable in the long term, efficien-
cies need to be generated within the health system including a
budget reallocation between secondary and primary care,
strengthening primary care to manage chronic conditions and raise
population awareness about NCD risk factors and disease manage-
ment, implementation of evidence-based selection and quality use of
medicines in both outpatient and inpatient settings, improve moni-
toring and regulation of prices and the supply chain; and alignment
of national treatment guidelines and clinical practice with interna-
tional best practices and evidence-based medicine.
Supplementary data
Supplementary data are available at HEAPOL online.
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